Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Current Assets (2016 - 2025)

Historic Current Assets for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $176.9 million.

  • Editas Medicine's Current Assets fell 3476.0% to $176.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.9 million, marking a year-over-year decrease of 3476.0%. This contributed to the annual value of $289.3 million for FY2024, which is 1511.43% down from last year.
  • According to the latest figures from Q3 2025, Editas Medicine's Current Assets is $176.9 million, which was down 3476.0% from $182.8 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Current Assets ranged from a high of $632.3 million in Q1 2021 and a low of $176.9 million during Q3 2025
  • For the 5-year period, Editas Medicine's Current Assets averaged around $382.5 million, with its median value being $356.8 million (2022).
  • Per our database at Business Quant, Editas Medicine's Current Assets soared by 4874.31% in 2021 and then tumbled by 3616.43% in 2025.
  • Over the past 5 years, Editas Medicine's Current Assets (Quarter) stood at $507.3 million in 2021, then dropped by 29.68% to $356.8 million in 2022, then decreased by 4.46% to $340.8 million in 2023, then fell by 15.11% to $289.3 million in 2024, then tumbled by 38.86% to $176.9 million in 2025.
  • Its Current Assets stands at $176.9 million for Q3 2025, versus $182.8 million for Q2 2025 and $224.8 million for Q1 2025.